EU/3/20/2296: Orphan designation for the treatment of marginal zone lymphoma
Table of contents
On 26 June 2020, orphan designation EU/3/20/2296 was granted by the European Commission to Kite Pharma EU B.V., Netherlands, for axicabtagene ciloleucel for the treatment of marginal zone lymphoma.
The sponsor’s address was updated in September 2021.
Treatment of marginal zone lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Kite Pharma EU B.V.
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: